SFP
TVRD

Sterling Financial Planning’s Tvardi Therapeutics TVRD Stock Holding History

Sterling Financial Planning’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20
Closed -$11K – 394
2020
Q4 		$11K Buy
+20
New +$10.5K 0.01% 257

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Sterling Financial Planning's TVRD Position: Q1 2021 in Review

Sterling Financial Planning sold out of Tvardi Therapeutics (TVRD) in Q1 2021, closing a stake of 20 shares — an estimated $11K sold.

Sterling Financial Planning first reported a position in TVRD in Q4 2020 and held it in 1 quarter. The position peaked at $11K in Q4 2020. 168 funds tracked by Wall St. Rank hold TVRD as of Q1 2021.

  • Sterling Financial Planning reported no remaining Tvardi Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Sterling Financial Planning sold 20 Tvardi Therapeutics shares in Q1 2021, an estimated $11K.
  • Sterling Financial Planning first reported a position in Tvardi Therapeutics in Q4 2020 and held it in 1 quarter.
  • Sterling Financial Planning's Tvardi Therapeutics position peaked at $11K in Q4 2020.
  • 168 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2021.

Based on Sterling Financial Planning's 13F filing for Q1 2021, filed 28 Apr 2021.